Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Leishmania donovani targets Dicer1 to downregulate miR-122, lower serum cholesterol, and facilitate murine liver infection.

Ghosh J, Bose M, Roy S, Bhattacharyya SN.

Cell Host Microbe. 2013 Mar 13;13(3):277-88. doi: 10.1016/j.chom.2013.02.005.

2.

115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.

Choudhury R, Das P, De T, Chakraborti T.

Immunobiology. 2013 Jan;218(1):114-26. doi: 10.1016/j.imbio.2012.02.008. Epub 2012 Feb 16.

PMID:
22440312
3.

The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani.

Rostan O, Gangneux JP, Piquet-Pellorce C, Manuel C, McKenzie AN, Guiguen C, Samson M, Robert-Gangneux F.

MBio. 2013 Sep 17;4(5):e00383-13. doi: 10.1128/mBio.00383-13.

4.
5.

Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease.

Sharma H, Estep M, Birerdinc A, Afendy A, Moazzez A, Elariny H, Goodman Z, Chandhoke V, Baranova A, Younossi ZM.

J Gastroenterol Hepatol. 2013 Aug;28(8):1410-5. doi: 10.1111/jgh.12268.

PMID:
23663110
6.

Involvement of CD4⁺ Foxp3⁺ regulatory T cells in persistence of Leishmania donovani in the liver of alymphoplastic aly/aly mice.

Tiwananthagorn S, Iwabuchi K, Ato M, Sakurai T, Kato H, Katakura K.

PLoS Negl Trop Dis. 2012;6(8):e1798. doi: 10.1371/journal.pntd.0001798. Epub 2012 Aug 21.

7.

Deficiency of p110δ isoform of the phosphoinositide 3 kinase leads to enhanced resistance to Leishmania donovani.

Khadem F, Mou Z, Liu D, Varikuti S, Satoskar A, Uzonna JE.

PLoS Negl Trop Dis. 2014 Jun 19;8(6):e2951. doi: 10.1371/journal.pntd.0002951. eCollection 2014 Jun.

8.

Role of cytosolic glyceraldehyde-3-phosphate dehydrogenase in visceral organ infection by Leishmania donovani.

Zhang WW, McCall LI, Matlashewski G.

Eukaryot Cell. 2013 Jan;12(1):70-7. doi: 10.1128/EC.00263-12. Epub 2012 Nov 2.

9.

Hyperlipidemia offers protection against Leishmania donovani infection: role of membrane cholesterol.

Ghosh J, Das S, Guha R, Ghosh D, Naskar K, Das A, Roy S.

J Lipid Res. 2012 Dec;53(12):2560-72. doi: 10.1194/jlr.M026914. Epub 2012 Oct 10.

10.

Therapeutic efficacy of artemisinin-loaded nanoparticles in experimental visceral leishmaniasis.

Want MY, Islamuddin M, Chouhan G, Ozbak HA, Hemeg HA, Dasgupta AK, Chattopadhyay AP, Afrin F.

Colloids Surf B Biointerfaces. 2015 Jun 1;130:215-21. doi: 10.1016/j.colsurfb.2015.04.013. Epub 2015 Apr 18.

PMID:
25936561
11.

Leishmania donovani activates SREBP2 to modulate macrophage membrane cholesterol and mitochondrial oxidants for establishment of infection.

Mukherjee M, Basu Ball W, Das PK.

Int J Biochem Cell Biol. 2014 Oct;55:196-208. doi: 10.1016/j.biocel.2014.08.019. Epub 2014 Sep 16.

PMID:
25218172
12.

Screening Leishmania donovani complex-specific genes required for visceral disease.

Zhang WW, Matlashewski G.

Methods Mol Biol. 2015;1201:339-61. doi: 10.1007/978-1-4939-1438-8_20.

PMID:
25388124
13.

MicroRNA-107, an oncogene microRNA that regulates tumour invasion and metastasis by targeting DICER1 in gastric cancer.

Li X, Zhang Y, Shi Y, Dong G, Liang J, Han Y, Wang X, Zhao Q, Ding J, Wu K, Fan D.

J Cell Mol Med. 2011 Sep;15(9):1887-95. doi: 10.1111/j.1582-4934.2010.01194.x.

14.
15.

Adaptation of Leishmania donovani to cutaneous and visceral environments: in vivo selection and proteomic analysis.

McCall LI, Zhang WW, Dejgaard K, Atayde VD, Mazur A, Ranasinghe S, Liu J, Olivier M, Nilsson T, Matlashewski G.

J Proteome Res. 2015 Feb 6;14(2):1033-59. doi: 10.1021/pr5010604. Epub 2015 Jan 13.

PMID:
25536015
16.

Novel arylimidamides for treatment of visceral leishmaniasis.

Wang MZ, Zhu X, Srivastava A, Liu Q, Sweat JM, Pandharkar T, Stephens CE, Riccio E, Parman T, Munde M, Mandal S, Madhubala R, Tidwell RR, Wilson WD, Boykin DW, Hall JE, Kyle DE, Werbovetz KA.

Antimicrob Agents Chemother. 2010 Jun;54(6):2507-16. doi: 10.1128/AAC.00250-10. Epub 2010 Apr 5.

17.
18.
20.

Supplemental Content

Support Center